trial summary · NCT07585136
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
Trial record from the TrialBase DB dataset, status RECRUITING, condition Bone Marrow Failure Syndrome, sponsored by St. Jude Children's Research Hospital. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to investigate mobilization and collection of HSPCs in patients with bone marrow failure syndromes (BMFS) using granulocyte-colony stimulating factor (otherwise known as Filgrastim) with plerixafor to demonstrate safety and feasibility of collecting HSPCs to advance gene therapy. Primary objective: \- To characterize the safety of Filgrastim plus plerixafor in participants with life threatening blood disorders as determined by the incidence of adverse events (AEs). Secondary Objectives: * To measure the mobilization effects of Filgrastim plus plerixafor in the peripheral blood in participants as determined by peak peripheral blood CD34+ counts. * To characterize the feasibility of HSPC mobilization using Filgrastim plus plerixafor as determined by peripheral blood CD34+ counts. * To estimate efficacy of Filgrastim plus plerixafor for HSPC mobilization and apheresis collection in participants as determined by the yield of CD34+ cells (CD34+ cells/kg).
Source record: https://clinicaltrials.gov/study/NCT07585136
Facts
| registry id | NCT07585136 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Bone Marrow Failure Syndrome |
| sponsor | St. Jude Children's Research Hospital |
| sponsor class | OTHER |
| enrollment | 12 |
| start date | 2026-11 |
| primary completion | 2028-12-01 |
| completion | 2029-07-01 |
| results posted | not reported |
Conditions
- Bone Marrow Failure Syndrome
Interventions
- Filgrastim
- Plerixafor
- Leukapheresis
Countries
- United States
Intervention types: DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.